Veronomics matches new and repurposable drugs to intractable cancers or infectious diseases by combining genomic gene/pathway essentiality screens with bioinformatics analyses and proprietary algorithms. We developed new or repurposed drugs targeting drug-resistant pancreatic and ovarian cancers and fusion oncogene-driven pediatric sarcomas. We seek seed funding to expand our IP and disease portfolio for out-licensing and internal development.